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OBJECTIVES: Diabetes-related minor hypoglycemic episodes (MHEs) have been 
found to be signiﬁcantly related to decreased treatment satisfaction. Unfortunately 
little is known regarding the impact of MHEs on work productivity and costs for 
people who work. METHODS: A US web-based survey of persons with diabetes was 
conducted. RESULTS: 6,756 persons with diabetes were surveyed. Of these 830 had 
at least one MHE in the past month, of whom 411 indicated working for pay, which 
is the population used for this analysis. Of the 411, 200 (48.7%) respondents had 
type 1 and 211 (51.3%) had type 2 diabetes. 290 (70.6%) were taking insulin and 
121 (29.4%) used only oral hypoglycemic agents. The mean age was 49.5 o 13.2, 
64.0% were females and average duration of diabetes was 15.8 o 12.7 years. 385 
(94%) reported MHEs, either at work or during sleep which affected their work, in 
the past year. For their latest MHE at work, the average amount of time respondents 
reported not functioning at their usual work productivity level (presenteeism) was 9.1 
hours. 34 subjects reported 1.0 days of absence from work after a MHE at the work 
place (e.g. leaving early or missing meetings). Additionally, 31 respondents had MHE 
during the night which resulted in 1.7 days of absence the following days. On average, 
these respondents used 6.9 extra blood sugar monitoring tests per MHE and $66.25 
out-of-pocket was spent on foods, glucose products, changes in transportation, etc. in 
the past month due to MHEs. CONCLUSIONS: It appears that lost productivity 
(presenteeism and absenteeism) and the costs of MHEs have been underestimated and 
should be considered an important part of diabetes management. Treatments which 
reduce MHEs would increase work productivity and decrease cost of care.
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OBJECTIVES: As in most countries, Diabetes Mellitus is a disease causing signiﬁcant 
burden to Turkey. The treatments and their beneﬁts affect not only the patient, but 
their friends, families and other relationships as well. Therefore, feedback regarding 
the quality of life of a Diabetes Mellitus patient is meaningful. The aim of this study 
was to determine the reliability and validity of the Diabetes Health Proﬁle-1 (DHP-1) 
for Turkish Diabetic patients. METHODS: The scale, which was translated into 
Turkish from English, again translated back into English by 2 independent translators, 
was applied to 45 diabetic patients for pre-test. After assessment of the results, the 
questionnaire was applied to 60 diabetic patients. Cronbach’s Alfa was used to assess 
reliability and factor analysis to assess dimensionality. The EuroQol-5D was used for 
concurrent validity. RESULTS: The internal consistency coefﬁcient (Cronbach’s alpha) 
of DHP-1was 0.86. Factor analysis of the scale revealed that it was composed of ﬁve 
factors with Eigenvalues 1, accounting for 74.4% of the total variance. All items of 
the Turkish DHP had a factor load ranging from 0.578 to 0.838. CONCLUSIONS: 
The DHP-1 has good validity and reliability for Turkish Diabetic patients.
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TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS 
GLARGINE OR DETEMIR AS BASAL INSULIN: RESULTS FROM THE LIVE-
COM STUDY
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OBJECTIVES: Although basal insulins glargine (GLA) or detemir (DET) appear to 
have similar clinical efﬁcacy for treatment of type 2 diabetes (T2D), there are several 
differences between these two regimens that could affect outcomes from a patient’s 
perspective. The purpose of this study was to compare treatment experiences (TE) and 
treatment satisfaction (TS) associated with insulin administration in T2D patients 
treated with either GLA or DET in a basal-bolus regimen for at least 6 months. 
METHODS: LIVE-COM (Long Acting Insulin Glargine versus Insulin Detemir Cost 
Comparison in Germany) was a non-interventional, cross-sectional, retrospective 
study performed between April and September 2008 in 138 randomly selected centers 
of primary care physicians in Germany. The study enrolled 1731 T2D patients with 
statutory health insurance status eligible for documentation when either treated with 
GLA (n  1150) or DET (n  581) as part of a basal-bolus regimen for at least 6 
months prior to documentation. Patients completed the Insulin Treatment Experience 
Questionnaire (ITEQ), a new condition-speciﬁc instrument assessing TE and TS, and 
the Diabetes Treatment Satisfaction Questionnaire (DTSQs). To examine differences   
between the two treatment group’s independent t-test and general linear models 
(GLMs) were used. RESULTS: Treatment experiences and satisfaction analyses were 
conducted with data from 1,718 per protocol patients (GLA: 1,141; DET: 577). ITEQ 
subscales (sleep, diabetes control, weight control), ITEQ total score differed between 
insulin groups and were clearly better (p  0.05) in GLA group (ITEQ total score: 
68.6 o 12.7 vs. 66.7 o 13.9, p  0.004). Differences in DTSQs total score failed to     
reach statistical signiﬁcance (28.8 o 5.9 vs. 28.2 o 5.8, p  0.064) Results of the GLMs 
indicate that differences between the insulin groups were stable after adjustment. 
CONCLUSIONS: Under real life conditions, our results indicate that glargine was 
associated with signiﬁcant higher treatment experiences as well as treatment satisfac-
tion compared to detemir among T2D patients treated in a basal-bolus regimen.
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OBJECTIVES: To evaluate the impact of comorbid depression in patients with T2DM 
on work productivity and activity impairment in France, Germany Italy, Spain and 
the UK. METHODS: Data were from the 2008 U.S. National Health and Wellness 
Survey (NHWS), an annual cross-sectional survey of self-reported health care behav-
iors, disease states, and outcomes of adults aged 18, translated for each country. A 
cohort of patients with T2DM without comorbid depression was compared to a 
cohort of T2DM with comorbid depression. Depression was deﬁned as afﬁrmative 
responses in the past month to: bothered by feeling down, depressed or hopeless; and 
bothered by having little interest or pleasure in doing things. The Work Productivity 
and Activity Impairment (WPAI) questionnaire measured productivity; regression 
models adjusted for gender, age, country, marital status, education and an adjusted 
Charlson Comorbidity Index score. RESULTS: Among 2668 respondents diagnosed 
with T2DM, 828 (31%) were female and 750 (28%) experienced symptoms of depres-
sion. Of 873 employed patients, 275 had symptoms of depression. After controlling 
for our covariates, employed patients with comorbid depression had signiﬁcantly 
worse levels of absenteeism [B  11.15, t  5.66; p  0.001] and impairment while at 
work (presenteeism) [B  20.96, t  11.72; p  0.001], and had signiﬁcantly more 
overall work loss [B  25.58, t  11.59; p  0.001]. For all respondents activity impair-
ment was also signiﬁcantly higher for patients with comorbid depression [B  22.76, 
t  21.40; p  0.001]. Germany has a greater amount of presenteeism, and work pro-
ductivity loss (p  0.05) than the other EU countries compared to the UK in this study; 
however, France, Germany, Italy and Spain patients experience signiﬁcantly less activ-
ity impairment than UK patients (p  0.05). CONCLUSIONS: Patients with T2DM 
and comorbid depression reported signiﬁcantly more absenteeism and presenteeism 
overall. Treating both diseases effectively might lessen burden of disease and related 
indirect costs; further research is needed to clarify geographical and cultural inﬂuence 
associated with lost productivity.
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OBJECTIVES: Treatment goals for acromegaly, an endocrine disorder characterized 
by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1), have 
centered around biochemical control. The objective of this study is to describe the 
health-related quality of life (HRQoL) burden and economic impact of acromegaly. 
METHODS: A review of the literature from the past 12 years was conducted using 
MEDLINE, Econlit, and EMBASE using QoL, economics, costs, and utility as search 
terms. Additional searches were conducted from article bibliographies and conference 
proceedings. Selected articles were speciﬁcally designed to examine HRQoL or direct 
medical costs associated with acromegaly in adults. RESULTS: Of 97 abstracts identi-
ﬁed, 57 (22 HRQoL, 37 economic) met selection criteria. HRQoL has been assessed 
for acromegaly using 15 distinct instruments. Patients with acromegaly consistently 
reported lower HRQoL than population-based controls. Acromegaly patients have 
HRQoL scores similar to HIV patients, and signiﬁcantly lower than patients with 
arthritis, chronic lung disease, diabetes and hypertension. Some studies showed that 
HRQoL improved with biochemical control, but results were not consistent. For the 
economic burden, the average direct medical costs per patient varied from $4,000 to 
$28,000 annually. Costs in the ﬁrst year after diagnosis were approximately 2–3x 
higher than other years. Estimated annual costs of care prior to diagnosis were roughly 
equivalent to annual costs after diagnosis. Lifetime costs exceeded $1,000,000 per 
patient. Key cost drivers were comorbidities, treatment strategy, and response to 
treatment. Patients not achieving biochemical control had total medical costs 1.6 times 
higher than those who were controlled. CONCLUSIONS: There is a substantial 
HRQoL and economic burden for acromegaly. Treatment and optimization of bio-
chemical control may lead to improvements in QoL and reductions in direct medical 
costs. Future areas of research should include a holistic evaluation of both costs and 
HRQoL on clinical consequences of alternative treatment strategies for acromegaly.
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OBJECTIVES: Linguistic validation of a diabetes knowledge questionnaire that is 
internationally acceptable and detects common misunderstandings and important 
educational needs. A rigorous methodology was employed to ensure conceptual 
equivalence and cultural relevance as well as harmonisation across countries. 
METHODS: The Audit for Diabetes Knowledge (ADKnowl) (104 Items in 23 sections) 
